Ionis Pharmaceuticals

IONSNASDAQ

Antisense oligonucleotide discovery and development platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

Filing figures as of June 30, 2026 · text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

IONS filings on EDGAR →

Cash & investments

$2.70B

at June 30, 2026 (10-Q)

Quarterly operating burn

$114M

average per quarter, Jan–Jun 2026

Cash runway

~71 months

$2.70B ÷ $114M per quarter

Shares outstanding

166.2M

cover page of the latest filing

Read from IONS's XBRL financial data; latest filing July 29, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Early revenue.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

Donidalorsen OLE: Donidalorsen in Hereditary angioedema prophylaxis — primary completion

2026-12

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Donidalorsen paediatric: Donidalorsen in Hereditary angioedema, ages 2 to <12 — primary completion

2029-06

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Olezarsen paediatric FCS: Olezarsen in Familial chylomicronemia syndrome — primary completion

2030-08

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
Tryngolzafamilial chylomicronemia syndromeApprovedNot disclosed▼
Donidalorsenhereditary angioedemaPhase 3Not disclosed▼
Olezarsensevere hypertriglyceridemiaPhase 3Not disclosed▼

Analysis

We have not yet written an analysis of Ionis Pharmaceuticals that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade IONS commission-free on Webullvia Webull · Affiliate

Comparable companies

Alnylam PharmaceuticalsSarepta TherapeuticsWave Life Sciences

Sponsored

Get premium IONS analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Ionis Pharmaceuticals has 81 Phase 2 or 3 studies on ClinicalTrials.gov: 58 completed, 6 stopped early, 17 ongoing.

58

Completed

6

Stopped early

17

Ongoing

Stopped early

  • NCT04441788Phase 2 · started 2020 · terminated

    ION-827359 in chronic bronchitis · n=60

    Reason given: Business Decision to Terminate Study

  • NCT04059406Phase 2 · started 2020 · terminated

    sapablursen in beta thalassemia intermedia · n=29

    Reason given: Favorable safety and tolerability were seen, but efficacy results in the mid-stage study did not meet Ionis' minimum target product profile to justify further development.

  • NCT03446144Phase 2 · started 2018 · withdrawn

    IONIS-FB-Lrx in geographic atrophy · n=0

    Reason given: Business objective change, no safety or efficacy concerns

  • NCT01647308Phase 2 · started 2012 · terminated

    ISIS-APOCIIIRX in type 2 diabetes · n=15

    Reason given: The study was terminated for business planning purposes. Assessments of APOCIIIRx in this population will be explored in a larger efficacy study

  • NCT00327626Phase 2 · started 2006 · withdrawn

    ISIS 113715 in type 2 diabetes mellitus · n=0

    Reason given: study was never started due to regional geopolitical conflict

  • NCT00330200Phase 2 · started 2005 · terminated

    ISIS 113715 in type 2 diabetes mellitus · n=2

    Reason given: Due to poor enrollment

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.